We are live on ! Find out more

Royalty Pharma

RPRX

Market cap $29.4B

65.93 USD

+1.11

1.71%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

65.93

0.00

0%

1 day

1.71%

5 days

3.83%

1 month

13.24%

3 months

11.41%

6 months

33.22%

Year to date

69.66%

1 year

79.79%

5 years

66.78%

10 years

48.16%

About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Employees: 100

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 50%

Neutral 46.7%

Negative 3.3%

The Motley Fool

Should You Buy Royalty Pharma Stock Before Nov. 4?

Royalty Pharma shares have surged ahead of the biotech funding company's Nov. 4 quarterly earnings release. It's unclear whether the company will knock it out of the park this quarter, as was the case with Q2 2026.

Should You Buy Royalty Pharma Stock Before Nov. 4?

Zacks Investment Research

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

The Motley Fool

3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell

Royalty Pharma buys drug royalties. Buying drug royalties provides pharmaceutical companies with cash up front while giving Royalty Pharma a long-term income stream.

3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell

Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.

Goldman Sachs says consumer-facing laggard stocks are the best way forward as earnings growth is set to slow next year and big tech stocks struggle.

Big tech is wobbling. Goldman Sachs says it's time to buy these 23 unloved stocks instead.

Royalty Pharma declares fourth quarter 2026 dividend

NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share.

Royalty Pharma declares fourth quarter 2026 dividend

Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026

Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.

Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026

Zacks Investment Research

Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again

The Motley Fool

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma offers exposure to a diversified portfolio of promising drug products and candidates. Its approach provides an optimal way to gain exposure to solid returns with minimal downside risk.

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts

Royalty Pharma NASDAQ: RPRX executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage.

Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts

The Motley Fool

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

See News Rankings

Price charts implemented using Lightweight Charts™